<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cell therapy on FinanClub</title>
    <link>https://finan.club/tags/cell-therapy/</link>
    <description>Recent content in Cell therapy on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sat, 02 Mar 2024 09:02:41 +0000</lastBuildDate><atom:link href="https://finan.club/tags/cell-therapy/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>SANA</title>
      <link>https://finan.club/us/sana/</link>
      <pubDate>Sat, 02 Mar 2024 09:02:41 +0000</pubDate>
      
      <guid>https://finan.club/us/sana/</guid>
      <description>score:46
Chances: Sana Biotechnology has successfully cleared IND for B-cell mediated autoimmune diseases with initial clinical data expected in 2024 Early data from ongoing ARDENT trial suggests the ability to dose safely, demonstrate the desired immune evasion profile, and early clinical efficacy Risks: Markets are awaiting the latest inflation numbers and the debate regarding soft vs hard landing is expected to persist on Wall Street High institutional ownership implies Sana Biotechnology&amp;rsquo;s stock price is sensitive to their decisions Score:46 chances characters count - risks characters count = 46</description>
    </item>
    
    <item>
      <title>IOVA</title>
      <link>https://finan.club/us/iova/</link>
      <pubDate>Mon, 19 Feb 2024 09:05:20 +0000</pubDate>
      
      <guid>https://finan.club/us/iova/</guid>
      <description>score:106
Chances: The U.S. health regulator has granted an accelerated approval for Iovance Biotherapeutics&amp;rsquo; cell therapy for advanced melanoma, making it the first such treatment for the deadliest form of skin cancer. The approval allows use in patients who have been previously treated with other therapies, but their cancer has spread to other parts of the body and cannot be removed with surgery, providing a significant market opportunity for Iovance.</description>
    </item>
    
  </channel>
</rss>
